Search
for
Sort by
Research 31–60 of 832
- Adverse events with finasteride or dutasteride: FAERS
- Development of phage-containing hydrogel for treating Enterococcus faecalis-infected wounds
- Analyzing real-world adverse events of spironolactone with the FAERS database
- Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
- Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
- Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
- Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study
- Association between finasteride with subjective memory deficits: a study from the NHANES and FAERS databases
- 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)
- Phytochemical analysis and antibacterial activities of Avicennia marina (Forssk.) Vierh. extracts against Vancomycin-resistant Enterococcus faecium
- 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)
- Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- A Gender Hypothesis of sex disparities in adverse drug events
- Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System
- A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
- FDA Reports of Alopecia as an Adverse Event to Isotretinoin
- Clinical Translation of Microbiome Research in Alopecia Areata: A New Perspective?
- Comment on “Low dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series”: Adding further evidence about side effects
- Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
- Evaluation of ameliorative efficiency of vitamin E and Saccharomyces cerevisiae yeast on arsenic toxicity in Black Bengal kids
- Treating Psoriasis: What Is New About Fumaric Acid Esters?